Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28171717
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Reversal of liver cirrhosis: current evidence and expectations
#MMPMID28171717
Jung YK
; Yim HJ
Korean J Intern Med
2017[Mar]; 32
(2
): 213-228
PMID28171717
show ga
In the past, liver cirrhosis was considered an irreversible phenomenon. However,
many experimental data have provided evidence of the reversibility of liver
fibrosis. Moreover, multiple clinical studies have also shown regression of
fibrosis and reversal of cirrhosis on repeated biopsy samples. As various
etiologies are associated with liver fibrosis via integrated signaling pathways,
a comprehensive understanding of the pathobiology of hepatic fibrogenesis is
critical for improving clinical outcomes. Hepatic stellate cells play a central
role in hepatic fibrogenesis upon their activation from a quiescent state.
Collagen and other extracellular material components from activated hepatic
stellate cells are deposited on, and damage, the liver parenchyma and vascular
structures. Hence, inactivation of hepatic stellate cells can lead to enhancement
of fibrolytic activity and could be a potential target of antifibrotic therapy.
In this regard, continued efforts have been made to develop better treatments for
underlying liver diseases and antifibrotic agents in multiple clinical and
therapeutic trials; the best results may be expected with the integration of such
evidence. In this article, we present the underlying mechanisms of fibrosis,
current experimental and clinical evidence of the reversibility of liver
fibrosis/cirrhosis, and new agents with therapeutic potential for liver fibrosis.
free
free
free
